Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 17/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 15/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21979018 | 0.81 | TLR9 (0.38) | TLR7TLR9CASR | |
| SCHEMBL30901324 | 0.81 | TLR9 (0.38) | TLR7TLR9CASR | |
| SCHEMBL22016488 | 0.77 | ATM (0.41) | — | |
| SCHEMBL22016181 | 0.77 | MAPK8 (0.40) | — | |
| SCHEMBL22017354 | 0.74 | PGR (0.44) | TLR9 | |
| SCHEMBL22017085 | 0.73 | KDM4E (0.46) | TLR9 | |
| SCHEMBL22031406 | 0.73 | NQO2 (0.54) | — | |
| SCHEMBL23606075 | 0.69 | QDPR (0.50) | TLR7TLR8TLR9 | |
| SCHEMBL22016182 | 0.69 | ATM (0.48) | — | |
| SCHEMBL22035473 | 0.69 | NTRK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | TLR7 596/4885TLR8 1892/4885TLR9 1482/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | TLR7 327/4885TLR8 1724/4885TLR9 1291/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | TLR7 596/4885TLR8 1892/4885TLR9 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.